Plus Therapeutics, Inc. (the "Company"), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, has announced a reverse stock split of its common stock at a ratio of 1-for-25. This decision was approved by the Company's Board of Directors and will take effect at 12:01 a.m. Eastern Time on April 2, 2026. Following the split, the Company's common stock will begin trading on The Nasdaq Capital Market under the existing trading symbol "PSTV". The reverse stock split aims to increase the per-share trading price of the Company's common stock to comply with the minimum $1.00 bid price requirement for continued listing on Nasdaq. As a result of the reverse stock split, the number of issued and outstanding shares will decrease from approximately 171,550,698 shares to approximately 6,862,027 shares. No fractional shares will be issued; instead, stockholders entitled to receive fractional shares will receive a cash payment equal to the fraction multiplied by the fair market value of a share of the Company's common stock. The Company has retained Broadridge Financial Services, Inc. as its exchange agent for the reverse stock split, and stockholders will receive instructions regarding the exchange of their shares. This strategic move is expected to enhance the Company's market position and facilitate future financing opportunities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.